ArticleScientific reports2016
Acute blockade of IL-25 in a colitis associated colon cancer model leads to increased tumor burden.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- ILC2s and their immune checkpoints in the antitumor response.Journal for immunotherapy of cancer · 2026Review
- The role of the tuft cell-interleukin-25 axis in the pathogenesis of inflammatory bowel disease.Frontiers in immunology · 2025Review
- Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.The Journal of clinical investigation · 2024Observational
- The IL-25/ILC2 axis promotes lung cancer with a concomitant accumulation of immune-suppressive cells in tumors in humans and mice.Frontiers in immunology · 2023Article
- TSLP, IL-33, and IL-25: Not just for allergy and helminth infection.The Journal of allergy and clinical immunology · 2022Review
- An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment forScience immunology · 2022Article
- Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis.Frontiers in immunology · 2022Review
- IL25 Enhanced Colitis-Associated Tumorigenesis in Mice by Upregulating Transcription Factor GLI1.Frontiers in immunology · 2022Article
- Interleukin 25 and its biological features and function in intestinal diseases.Central-European journal of immunology · 2022Review
- Innate lymphoid cells in early tumor development.Frontiers in immunology · 2022Review
- Type 2 immunity in intestinal homeostasis and inflammatory bowel disease.Biochemical Society transactions · 2021Review
- Inflammatory Mediators and Gut Microbial Toxins Drive Colon Tumorigenesis by IL-23 Dependent Mechanism.Cancers · 2021Article
- Interleukin-25: New perspective and state-of-the-art in cancer prognosis and treatment approaches.Cancer medicine · 2021Review
- Interleukin 25 (IL-25) expression in cholangiocarcinoma.Molecular and clinical oncology · 2020Article
- Dual-Functionalized MSCs that Express CX3CR1 and IL-25 Exhibit Enhanced Therapeutic Effects on Inflammatory Bowel Disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers.Journal of oncology · 2019Review
- IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chronic inflammation within the gastrointestinal tract results in an increased risk for developing colorectal cancer. Epithelial cytokines, including interleukin-25 (IL-25), are produced in the colon and are critical for protection from parasites, but can also be pathogenic in the context of inflammatory bowel diseases and allergy. Whether IL-25 is involved in the progression from inflammation to cancer is still largely unexplored. Using a well-established murine model for colitis-induced colon cancer; we aimed to determine the role of IL-25 in this process. We found that acute IL-25 blockade resulted in greater tumor burdens compared to isotype control treated mice. Histologically, α-IL-25 treated mice had increased colitis scores compared to mice receiving isotype control antibody, as well as decreased eosinophilia. This is the first study to explore the therapeutic potential of using an IL-25 blocking antibody during a chronic inflammatory setting. Taken together these data suggest that IL-25 plays an inhibitory role in the growth and development of colonic tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.